Page last updated: 2024-12-06

du-21220

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID31729
CHEMBL ID83063
CHEBI ID91775
SCHEMBL ID4430018
MeSH IDM0019135

Synonyms (39)

Synonym
CHEMBL83063
BRD-A59174698-003-02-9
BSPBIO_002955
SPECTRUM_001418
du-21220
ritodrina
SPECTRUM5_001225
ritodrine
KBIOSS_001898
KBIO2_004466
KBIO2_001898
KBIO3_002455
KBIO2_007034
KBIOGR_000796
SPBIO_001526
SPECTRUM3_001458
SPECTRUM4_000438
SPECTRUM2_001423
L000737
4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
du21220
NCGC00015887-03
NCGC00015887-05
SCHEMBL4430018
4-(1-hydroxy-2-([2-(4-hydroxyphenyl)ethyl]amino)propyl)phenol #
benzyl alcohol, p-hydroxy-.alpha.-[1-[(p-hydroxyphenethyl)amino]ethyl]-, erythro-
IOVGROKTTNBUGK-UHFFFAOYSA-N
ritodrin
erythro-p-hydroxy-.alpha.-[1-[(p-hydroxyphenethyl)amino]ethyl]benzyl alcohol
benzenemethanol, 4-hydroxy-.alpha.-[1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (r*,s*)-
AB00053608_11
4-(1-hydroxy-2-{[2-(4-hydroxyphenyl)ethyl]amino}propyl)phenol
CHEBI:91775
SBI-0051661.P002
Q27163579
BRD-A59174698-003-12-8
4-hydroxy-alpha-[1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]benzenemethanol
4635-27-2
DTXSID10860298

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This suggests that aggressive continued tocolysis with multiple agents can be safe and efficacious with appropriate evaluation."( Safety and efficacy of combined ritodrine and magnesium sulfate for preterm labor: a method for reduction of complications.
Coleman, FH, 1990
)
0.28
" The side effect rate was low as well for palpitation as for tremor."( Efficacy, safety and tolerance of oral sustained-release ritodrine given after intravenous administration in the treatment of premature labor.
Hendrickx, B; Thoumsin, H; van Assche, A, 1990
)
0.28
" Tocolysis with indomethacin was associated with no maternal side effects, whereas tocolysis with ritodrine hydrochloride was associated with a 24% incidence of serious cardiovascular and metabolic adverse effects prompting discontinuation of the drug."( Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study.
Angel, JL; Knuppel, RA; Morales, WJ; O'Brien, WF; Smith, SG, 1989
)
0.28
" In comparison with these agents, it seems relatively safe and the side effects are usually well tolerated."( Ritodrine hydrochloride: a betamimetic agent for use in preterm labor. I. pharmacology, clinical history, administration, side effects, and safety.
Barden, TP; Merkatz, IR; Peter, JB, 1980
)
0.26
" In addition, intravenous therapy was terminated more frequently as a result of maternal adverse events in the ritodrine group (29."( Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study.
Boucher, M; Cohen, H; Dansereau, J; Fejgin, M; Glezerman, M; Hochner-Celnikier, D; Liston, RM; Mazor, M; Mohide, PT; Moutquin, JM; Rabinovici, J; Shalev, E; Sherman, D; Zimmer, EZ, 2000
)
0.31
"Atosiban was comparable in clinical effectiveness to conventional ritodrine therapy but was better tolerated than ritodrine, with no evidence of significant maternal or fetal adverse events."( Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study.
Boucher, M; Cohen, H; Dansereau, J; Fejgin, M; Glezerman, M; Hochner-Celnikier, D; Liston, RM; Mazor, M; Mohide, PT; Moutquin, JM; Rabinovici, J; Shalev, E; Sherman, D; Zimmer, EZ, 2000
)
0.31
" Maternal side effects, particularly cardiovascular adverse events (8."( Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group.
, 2001
)
0.31
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Safety was assessed as the numbers of maternal adverse events and neonatal morbidity."( Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women.
Cho, YK; Kim, A; Lee, Y; Park, YW; Shim, JY; Yang, JH; Yoon, BH, 2006
)
0.33
" Maternal adverse events related to therapy were reported less frequently in the atosiban group (7."( Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women.
Cho, YK; Kim, A; Lee, Y; Park, YW; Shim, JY; Yang, JH; Yoon, BH, 2006
)
0.33
" However, several adverse effects of ritodrine therapy, including liver damage, have been noted."( Serum amyloid A upsurge precedes standard biomarkers of hepatotoxicity in ritodrine-injected mice.
Fujimura, A; Fujiwara, Y; Koshimizu, TA; Sato, J; Tsuchiya, H; Tsuda, H; Yamada, T, 2013
)
0.39
" Moreover, as the combination did not cause severe maternal side effects, it may be considered as a safe and effective method to prolong gestation in patients with preterm labor."( The influence of ritodrine alone or in combination with nifedipine on maternal cardiovascular side effects and pregnancy outcomes.
Bae, JY; Hwang, I; Kim, MJ; Seong, WJ, 2014
)
0.4
" This study aimed to investigate the relationship between adverse drug events caused by ritodrine and the CACNA1C polymorphisms in preterm labor patients."( Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.
Baek, MY; Chung, JE; Gwak, HS; Hwang, HS; Kim, YJ; Lee, GY; Lee, KE; Park, JY; Seong, JW; Yee, J, 2017
)
0.46
"Data were collected from medical records including maternal age, gestational age, body mass index, dilation score, effacement score, modified Bishop score, maximum infusion rate, and adverse drug events."( Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.
Baek, MY; Chung, JE; Gwak, HS; Hwang, HS; Kim, YJ; Lee, GY; Lee, KE; Park, JY; Seong, JW; Yee, J, 2017
)
0.46
"One hundred eighty-six patients were included, 33 of whom had adverse drug events."( Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.
Baek, MY; Chung, JE; Gwak, HS; Hwang, HS; Kim, YJ; Lee, GY; Lee, KE; Park, JY; Seong, JW; Yee, J, 2017
)
0.46
"This study showed that CACNA1C gene polymorphisms could alter the probability of adverse drug event risk when ritodrine is used in preterm labor."( Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.
Baek, MY; Chung, JE; Gwak, HS; Hwang, HS; Kim, YJ; Lee, GY; Lee, KE; Park, JY; Seong, JW; Yee, J, 2017
)
0.46
" This study was designed to identify associations between β2-adrenergic receptor (ADRB2) polymorphisms and adverse drug events (ADEs) in patients with preterm labor treated with ritodrine."( Association between ß2-adrenergic receptor gene polymorphisms and adverse events of ritodrine in the treatment of preterm labor: a prospective observational study.
Choi, SA; Chung, JE; Gwak, HS; Hwang, HS; Kim, YJ; Lee, KE; Park, JY; Yee, J, 2017
)
0.46
" However, it can cause unexpected serious adverse reactions, such as pulmonary oedema, pulmonary congestion, and tachycardia."( Deleterious genetic variants in ciliopathy genes increase risk of ritodrine-induced cardiac and pulmonary side effects.
Hwang, HS; Kim, JH; Kim, YJ; Kwon, EJ; Min, BJ; Park, Y; Seo, H; Yoo, K; You, YA, 2018
)
0.48
" Thus, in this study we investigated the safety of Rito in the treatment of imminent preterm birth, with a particular focus on the adverse effects (AEs) on fetuses and newborn infants."( The safety of ritodrine hydrochloride: Adverse effects on fetuses and newborns.
Ito, A; Yonaga, Y, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" None of the pharmacokinetic parameters differed according to dose or injection site."( Pharmacokinetics and pharmacodynamics of ritodrine after intramuscular administration to pregnant women.
Caritis, SN; Chiao, JP; Cotroneo, M; Habucky, K; Smith, M; Venkataramanan, R, 1990
)
0.28
"Dosing regimens for ritodrine are based in large part on pharmacokinetic studies performed with nonpregnant subjects."( Effect of pregnancy on ritodrine pharmacokinetics.
Caritis, SN; Lin, LS; Venkataramanan, R; Wong, LK, 1988
)
0.27
"To establish a rational ritodrine therapy in relation to serum ritodrine concentration, we examined 14 twin pregnancy patients and determined their pharmacokinetic data."( Ritodrine pharmacokinetics in twin pregnancy patients.
Hayakawa, T; Inotsume, N; Koga, Y; Konda, A; Nodai, A; Soma, M; Toda, T; Yoshida, H, 2008
)
0.35
"The twin pregnancy patients all exhibited linear ritodrine pharmacokinetic profiles."( Ritodrine pharmacokinetics in twin pregnancy patients.
Hayakawa, T; Inotsume, N; Koga, Y; Konda, A; Nodai, A; Soma, M; Toda, T; Yoshida, H, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The following pharmacokinetic parameters were calculated, using the non-compartmental model: Cmax, AUC0-t, AUC0-INF, t1/2, Vd/f, and Aet after each administration."( Pharmacokinetics and pharmacodynamics of ritodrine hydrochloride administered orally and intramuscularly to female healthy volunteers.
Bertolini, A; Bo, LD; Cantoni, V; Coa, K; Fontana, E; Ismaili, S; Marzo, A; Tavazzi, S; Zava, D, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" The first treatment consisted of the administration of ritodrine and a placebo; in the second, ritodrine was combined with indomethacin."( A study of indomethacin combined with ritodrine in threatened preterm labor.
Cañas, E; Cararach, V; Edo, A; Gamissans, O; Puerto, B; Ribas, J, 1978
)
0.26
" Rofecoxib combined with ritodrine had a synergic effect."( In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents.
Benchaib, M; Doret, M; Gharib, C; Mellier, G; Pasquier, JC; Piacenza, JM, 2002
)
0.31
"To compare the influence of ritodrine alone or in combination with nifedipine on maternal side effects and suppressing preterm labor."( The influence of ritodrine alone or in combination with nifedipine on maternal cardiovascular side effects and pregnancy outcomes.
Bae, JY; Hwang, I; Kim, MJ; Seong, WJ, 2014
)
0.4
" We estimated the cytogenetic effect of ritodrine administered as maternal therapy, alone or in combination with smoking, in women and their neonates."( Genotoxic effect of tocolytic drug ritodrine in combination with smoking during pregnancy.
Galazios, G; Kareli, D; Kontomanolis, E; Lialiaris, T; Liberis, A; Nikas, I; Nikolettos, N; Pouliliou, S; Psillaki, A, 2016
)
0.43
"The time-depended genotoxic, cytostatic and cytotoxic action of ritodrine alone or in combination with smoking suggests that its administration should not exceed the time period of a month."( Genotoxic effect of tocolytic drug ritodrine in combination with smoking during pregnancy.
Galazios, G; Kareli, D; Kontomanolis, E; Lialiaris, T; Liberis, A; Nikas, I; Nikolettos, N; Pouliliou, S; Psillaki, A, 2016
)
0.43
" Patients were divided into a research group receiving ritodrine combined with atosiban, owing to having no response to ritodrine alone (n=30), and a control group receiving ritodrine alone (n=22)."( Atosiban Combined with Ritodrine for Late Threatened Abortion or Threatened Premature Labor Patients with No Response to Ritodrine: A Clinical Trial.
Chen, H; Fu, S; Liu, Y; Mo, H; Tan, J; Xie, H; Xu, Q; Zhang, J; Zhong, Y; Zhu, L, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" A mean bioavailability of 26% (range 22%-32%) was estimated after the 4th day of treatment (steady state)."( Biopharmaceutical aspects of ritodrine retard in pregnant women.
Essed, GG; Struyker Boudier, HA; Van Zijl, JA,
)
0.13
" The bioavailability of this application form was assessed in a clinical study including 11 patients."( A new administration form of ritodrine. Ritodrine plasma levels with sustained-release capsules in a steady state.
de Haan, J; Essed, GG; Struyker Boudier, HA; van Elferen, LW, 1987
)
0.27
" In this respect, a daily dose of 60 mg, 6 X 10 mg, administered by oral route is probably too low; moreover, the bioavailability of the drug by this route was quite different in two volunteers."( Ritodrine serum levels: influence of dose and route of administration.
Desager, JP; Harvengt, C; Thomas, K; Van Lierde, M, 1984
)
0.27
" The bioavailability of the oral formulation was 30% of the parenteral preparations."( Serum level of ritodrine in man.
de Zoeten, LW; Gandar, R; van der Schoot, JB, 1980
)
0.26
"The beta2-adrenoceptor agonist ritodrine has a bioavailability of 30% due to its presystemic metabolism and sulphation is an important metabolic route."( Ritodrine sulphation in the human liver and duodenal mucosa: interindividual variability.
Giulianetti, B; Giuliani, L; Gomeni, R; Nervi, M; Pacifici, GM; Quilici, MC; Spisni, R,
)
0.13
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Ritodrine is known to undergo extensive presystemic sulfation in the intestinal mucosa, and its bioavailability is as low as 30%."( Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3.
Hiratsuka, A; Nishimuta, H; Ogura, K; Ohtani, H; Sawada, Y; Tsujimoto, M, 2005
)
0.33
"Sulfation of ritodrine by SULT1A3 was much higher than that by SULT1A1, suggesting that the bioavailability of ritodrine may be limited by intestinal SULT1A3."( Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3.
Hiratsuka, A; Nishimuta, H; Ogura, K; Ohtani, H; Sawada, Y; Tsujimoto, M, 2005
)
0.33
"Our results suggest that concomitant ingestion of beverages such as green tea and black tea may increase the bioavailability of orally administered ritodrine, and perhaps other beta2-agonists, and lead to an increase in the clinical effects or adverse reactions."( Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3.
Hiratsuka, A; Nishimuta, H; Ogura, K; Ohtani, H; Sawada, Y; Tsujimoto, M, 2005
)
0.33
" Moreover, the deconvolution analyses demonstrated that a prolonged high absorption rate could be achieved in vivo best with Tablet B/MC."( Preparation and evaluation of ritodrine buccal tablets for rational therapeutic use.
Onishi, H; Sakata, O; Yumoto, K, 2014
)
0.4
"The pharmacokinetic parameters for 0 - infinite time and the absorption rate were calculated based on the plasma level-time profiles in the intravenous (1 mg/kg), buccal (10 mg/kg) and intragastric (10 mg/kg) dosings using rats."( Oral Biodisposition Study of Ritodrine after Its Buccal Administration in Rats.
Onishi, H; Sakata, O; Yumoto, K, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Isoprenaline, salbutamol and ritodrine caused a dose-dependent reduction of the spontaneous contractions of the pregnant myometrium and a dose-related and parallel shift to the right of the isoprenaline dose-response curve was obtained with butoxamine but not with practolol."( Beta-adrenoceptors in the pregnant and non-pregnant myometrium of the goat and cow.
Larsen, JJ, 1979
)
0.26
"Fifty pregnant women admitted consecutively on account of threatened abortion or premature labour and treated with Ritodrine and Verapamil intravenously in the usual dosage were investigated with respect to creatine kinase activity and, in the event of a raised level, its isoenzyme creatine kinase--MB."( [Does myocardial damage arise as a result of administration of tocolytic drugs? (author's transl)].
Dienstl, F; Lechner, W, 1979
)
0.26
"Fifty pregnant women admitted consecutively on account of threatened abortion or premature labour and treated with Ritodrine and Verapamil intravenously in the usual dosage were investigated with respect to creatine kinase activity and, in the event of a raised level, its isoenzyme creatine kinase--MB."( [Does myocardial damage arise as a result of administration of tocolytic drugs? (author's transl)].
Dienstl, F; Lechner, W, 1979
)
0.26
" We concluded that high oral doses of magnesium therapy (4 x 3 gr) potentiate the effects of intravenous beta-agonists, allowing a reduction of the dosage needed and a better "tolerance"."( [Contribution of magnesium gluconate in intravenous tocolysis with ritodrine].
Ally, K; Lambotte, R; Nicolas, A; Thoumsin, H, 1992
)
0.28
" Duration of exposure to tocolysis was at least 30 days (30-180 days) with an oral dosage of 10 mg 3 times daily."( Transient electrocardiographic changes suggesting myocardial ischaemia in newborn infants following tocolysis with beta-sympathomimetics.
Agnetti, A; De Luca, F; Di Pasquale, G; Gemelli, M; Leonardi, R; Mami, C; Manganaro, R; Rando, F, 1990
)
0.28
" The remaining 41 patients started all with an intravenous treatment followed by oral treatment with sustained-release ritodrine at a daily dosage of 120 mg per day until the 36th week of gestation."( Efficacy, safety and tolerance of oral sustained-release ritodrine given after intravenous administration in the treatment of premature labor.
Hendrickx, B; Thoumsin, H; van Assche, A, 1990
)
0.28
"The oral dosing regimen for ritodrine was based in large part on kinetic data obtained in nonpregnant subjects."( Pharmacokinetics of orally administered ritodrine.
Caritis, SN; Chiao, JP; Cotroneo, M; Venkataramanan, R, 1989
)
0.28
" Additional studies are needed to better define dose-response curves for the intramuscular administration of ritodrine hydrochloride."( Intramuscular versus intravenous ritodrine hydrochloride for preterm labor management.
Benedetti, T; Creasy, RK; Gonik, B; Lee, AF, 1988
)
0.27
" These data indicate that dosing regimens for ritodrine based on studies of nonpregnant subjects may be subject to considerable error."( Effect of pregnancy on ritodrine pharmacokinetics.
Caritis, SN; Lin, LS; Venkataramanan, R; Wong, LK, 1988
)
0.27
" An oral 50 gm, 1-hour glucose challenge test was done 48 hours after terbutaline dosing began."( Carbohydrate intolerance in patients receiving oral tocolytics.
Angel, JL; Knuppel, RA; Morales, WJ; O'Brien, WF; Sims, CJ, 1988
)
0.27
"A sustained-release administration form of oral ritodrine was introduced to cope with the problem of the short dosage interval inherent to conventional oral ritodrine administration."( A new administration form of ritodrine. Ritodrine plasma levels with sustained-release capsules in a steady state.
de Haan, J; Essed, GG; Struyker Boudier, HA; van Elferen, LW, 1987
)
0.27
" Results were viewed on a mg/kg/minute ritodrine dosage basis."( The influence of intravenous solution content on ritodrine-induced metabolic changes.
Argubright, KF; Dunn, TS; Perkins, RP; Skipper, BJ; Varela-Gittings, F, 1987
)
0.27
" Tocolytic dosage was adjusted to maintain mean uterine contraction frequency of less than 4/hr."( Detection of preterm labor by ambulatory monitoring of uterine activity for the management of oral tocolysis.
Gill, PJ; Katz, M; Newman, RB, 1986
)
0.27
"The effects of two dosage schedules of nicardipine, a calcium-entry blocker, were studied in the pregnant rabbit during induced preterm uterine contractions and compared with the effects of ritodrine hydrochloride."( Cardiovascular and tocolytic effects of nicardipine HCl in the pregnant rabbit: comparison with ritodrine HCl.
Holbrook, RH; Katz, M; Lirette, M, 1987
)
0.27
" However, spontaneous premature labor is associated with accelerated lung maturation, and accordingly the present results do not contradict the use of a low dosage of betasympathomimetic drug to delay preterm delivery."( Effects of betamethasone and ritodrine on the fetal secretion of lung surfactant.
Hallman, M; Raivio, K; Sipinen, S; Teramo, K, 1985
)
0.27
" Recommendations for selecting patients most likely to benefit from ritodrine are given, together with the dosage and administration schedules that have been found most effective."( Ritodrine hydrochloride: a betamimetic agent for use in preterm labor. I. pharmacology, clinical history, administration, side effects, and safety.
Barden, TP; Merkatz, IR; Peter, JB, 1980
)
0.26
" Pregnant rats were treated with long and short dosage schedules."( Effects of maternal ritodrine therapy on fetal rat brain development.
Shapiro, DL; Zmora, E, 1982
)
0.26
" 3) The administration of ritodrine and terbutaline at the last trimester of pregnancy led to the increased, showing dose-response relationship, in the heart rate of mother and fetus in rabbits."( [beta 1, beta 2-effects of ritodrine in pregnant animal experiments (author's transl)].
Chimura, T; Inoue, K, 1981
)
0.26
" 3) The action of c-AMP related substances on the circulatory systems was manifested as the dose-response of beta 1 action to the maternal blood pressure, maternal and fetal heart rate."( [Beta 1-, beta 2-effects of ritrodine and terbutaline in the treatment of preterm labor (author's transl)].
Chimura, T; Inoue, K; Mitsui, T, 1981
)
0.26
" These actions of ritodrine were much the same as those of isoprenaline but the dose-response curves of all parameters were shifted to the right."( Effects of ritodrine, a beta 2-adrenoceptor agonist, on smooth muscle cells of the myometrium of pregnant rats.
Izumi, H; Kishikawa, T, 1982
)
0.26
"The purpose of the study was to determine if the adjunctive administration of magnesium sulfate with ritodrine would result in decreased dosage requirements of ritodrine, and, therefore, decrease the incidence of ritodrine-associated side effects."( Adjunctive use of magnesium sulfate with ritodrine for preterm labor tocolysis.
Ferguson, JE; Hensleigh, PA; Kredenster, D, 1984
)
0.27
" They were treated by intravenous administration of Ritodrine, the dosage varying between 100 and 400 micrograms per minute."( [Intravenous administration of ritodrine to pregnant insulin-dependent diabetics. Metabolic impact].
Buysschaert, M; de Hertogh, R; Loumaye, R; Thomas, K; Van Lierde, M, 1982
)
0.26
" Results of analysis of pure drugs and their dosage forms by the proposed method were in good agreement with either a reported derivative spectrophotometric procedure or the USP XXII method for etilefrine hydrochloride and ritodrine hydrochloride, respectively."( Spectrophotometric determination of etilefrine hydrochloride and ritodrine hydrochloride through nitrosation and subsequent cobalt chelation.
Bakry, RS; Belal, SF; el Walily, AM, 1995
)
0.29
" We guess that SP can be used in well regulated dosed with least side effects to arrest preterm labor on human being in the future."( The effect of spironolactone on the rat uterus.
Coksevim, B; Tayyar, M, 1994
)
0.29
" Maternal pulse and BP, fetal heart rate and heart size, and all Doppler indices were normal, without demonstrable dose-response effects."( Fetal cardiac effects of oral ritodrine tocolysis.
Blackstone, J; Friedman, DM; Hoskins, IA; Young, BK, 1994
)
0.29
" A twofold to threefold increase in the maximum recommended oral dosage of ritodrine should be considered, especially for patients who had previously required relatively high intravenous infusion rates (> 100 micrograms/min)."( Currently recommended oral regimens for ritodrine tocolysis result in extremely low plasma levels.
Dulitzky, M; Friedman, SA; Mashiach, S; Schiff, E; Sibai, BM; Sivan, E; Terry, S, 1993
)
0.29
" Tocolytic selection was similar in both groups, although the dosage per hour was significantly greater with long-term therapy."( Long-term intravenous tocolytic therapy.
Bruner, JP; Bruner, TA; Sarno, AP, 1997
)
0.3
"A simple, accurate, and rapid method for the quantitative determination of ritodrine hydrochloride (RTH) and isoxsuprine hydrochloride (ISH) in both pure and dosage forms, is described."( Spectrophotometric determination of ritodrine and isoxsuprine hydrochlorides using 4-aminoantipyrine.
Manju, BG; Revanasiddappa, HD,
)
0.13
"Two simple and sensitive spectrophotometric methods are described for the determination of ritodrine hydrochloride (RTH) in both pure and dosage forms."( Spectrophotometric methods for the determination of ritodrine hydrochloride and its application to pharmaceutical preparations.
Manju, B; Revanasiddappa, HD, 2001
)
0.31
"Contractile activity was assessed by calculating the area under the curve, to obtain a dose-response curve of each drug."( In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents.
Benchaib, M; Doret, M; Gharib, C; Mellier, G; Pasquier, JC; Piacenza, JM, 2002
)
0.31
" However, the preferred type of beta-adrenergic receptor agonist and dosage are unclear."( Acute tocolysis for uterine activity reduction in term labor: a review.
de Heus, R; Derks, JB; Mulder, EJ; Visser, GH, 2008
)
0.35
"Almost double the dosage of racemic ritodrine was required to prolong pregnancies with twins compared with those of singletons (2."( Pharmacokinetics of ritodrine diastereomers in patients pregnant with singletons and twins.
Hayakawa, T; Inotsume, N; Ito, T; Konda, A; Toda, T; Yoshida, H, 2009
)
0.35
"The purpose of this study was to identify the effects of abdominal breathing on state anxiety, stress and tocolytic dosage for pregnant women in preterm labor."( [Effects of abdominal breathing on state anxiety, stress, and tocolytic dosage for pregnant women in preterm labor].
Song, JE; Yu, WJ, 2010
)
0.36
" "The Ritodrine dosage for the experimental group will be lower than that of the control group" was supported."( [Effects of abdominal breathing on state anxiety, stress, and tocolytic dosage for pregnant women in preterm labor].
Song, JE; Yu, WJ, 2010
)
0.36
" Our experience suggests that multidrug therapy with Sivelestat offers a new therapeutic strategy for preterm labor, but further investigations of the indications, administration period and dosage are required."( Initial experience using Sivelestat to manage preterm labor with a bulging fetal membrane in pregnant women.
Masaoka, N; Nakajima, Y, 2012
)
0.38
"Although ritodrine (RD)-hydrochloride (HCl), named RD-HCl, is widely used in the treatment of premature labor by intravenous prolonged infusion or frequent oral dosing of tablets, those administrations often lower patients' quality of life (QOL) or cause undesirable side effects, such as tachycardia; therefore, in this study, the potential usefulness of buccal administration as a novel administration method was examined in vivo."( In vivo absorption study of ritodrine hydrochloride in the buccal administration to rats.
Onishi, H; Sakata, O, 2013
)
0.39
"Buccal application of RD-HCl was demonstrated to be a potentially useful dosing method in the treatment of premature labor with RD-HCl."( In vivo absorption study of ritodrine hydrochloride in the buccal administration to rats.
Onishi, H; Sakata, O, 2013
)
0.39
"Ritodrine hydrochloride (RD-HCl) tablets containing alginate (AL) and lactose (LC) with or without microcrystalline cellulose (MC) as excipients were produced as a buccal dosage form."( Preparation and evaluation of ritodrine buccal tablets for rational therapeutic use.
Onishi, H; Sakata, O; Yumoto, K, 2014
)
0.4
"A new, simple, sensitive and rapid spectrofluorimetric method has been developed for determination of certain adrenergic agonists such as isoxsuprine hydrochloride, ritodrine hydrochloride and etilefrine hydrochloride in their pure forms and pharmaceutical dosage forms."( Spectrofluorimetric determination of certain adrenergic agonist drugs in their pure forms and pharmaceutical formulations: Content uniformity test application.
Attia, TZ; Badr El-Din, KM, 2017
)
0.46
" As a result, buccal dosing of RD solution was found to be useful for the maintenance of effective plasma concentration."( Oral Biodisposition Study of Ritodrine after Its Buccal Administration in Rats.
Onishi, H; Sakata, O; Yumoto, K, 2017
)
0.46
" It was suggested that the buccal dosing of RD should be acceptable even in the repeated manner as an alternative to the intravenous or oral administration of RD."( Oral Biodisposition Study of Ritodrine after Its Buccal Administration in Rats.
Onishi, H; Sakata, O; Yumoto, K, 2017
)
0.46
" The proposed methods were validated according to International Conference on Harmonization guidelines and successfully applied for the determination of ritodrine hydrochloride in bulk powder, laboratory prepared mixtures and pharmaceutical dosage form with good accuracy and precision."( Stability-Indicating Chromatographic Methods for the Investigation of Ritodrine Hydrochloride Stability and Characterization of the Oxidative Degradation Product.
Abdallah, OM; El-Olemy, A; Eldin, AIH; Rashed, NS, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
benzyl alcoholsCompounds containing a phenylmethanol skeleton.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency20.93100.001310.157742.8575AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.02400.00301.17839.7724AID220923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-3 adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.19050.00010.71753.0000AID220925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID220925Agonistic activity towards beta-3 adrenoceptor. Mean concentration required to produce 50% relaxation of detrusor before the addition in the ferret detrusor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID220913Increase in BPM in isolated rat atria.2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID220927Activity compared to that observed following forskolin (10e -5).2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID220923Agonistic activity towards beta-2 adrenoceptor. Mean concentration required to produce 50% inhibition of uterine contraction2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID233231Concentration ratio of beta-2 (EC50) to beta3 (EC50)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1136412Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID233233Concentration ratio of beta-3 (EC50) to beta-1 (EC50)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (930)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990479 (51.51)18.7374
1990's207 (22.26)18.2507
2000's129 (13.87)29.6817
2010's86 (9.25)24.3611
2020's29 (3.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.27 (24.57)
Research Supply Index7.05 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials153 (15.39%)5.53%
Reviews62 (6.24%)6.00%
Case Studies178 (17.91%)4.05%
Observational5 (0.50%)0.25%
Other596 (59.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]